TheraVet announces a partnership significantly expanding TheraVet?s bone substitutes portfolio with 2 new exclusive and complementary bone graft lines, 3D-bioprinted bone endoprostheses for patient-tailored bone grafting surgeries & development of novel generation proprietary products. An exclusive worldwide distribution agreement with Innotere, TheraVet broadens its offer of bone substitutes to the vet orthopedic surgeons with 2 new exclusive lines of biomaterials: first with first-in-kind ready-to-use injectable calcium phosphate-based bone cement pastes with prolonged working time particularly well-suited for minimally invasive complex bone grafting procedures and second with biosynthetic granules of ultra-fine size. Moreover, TheraVet adds to its portfolio 3D-bioprinted calcium-phosphate-based bone substitutes. This technology allows the manufacturing of complex implants specifically designed according to patient and surgeon needs while ensuring optimal physico-chemical, biocompatibility and resorbability properties. One contemplated application is the supply of personalized biocompatible endoprotheses in the management of canine osteosarcoma. The new-generation bone substitutes will be jointly developed. These R&D programs relate to the design, development and industrialization of innovative bone substitutes; with enhanced rheofluidifying properties in order to facilitate their injectability, increase their workability, and globally improve their ergonomics, with improved osteogenic/bone-forming properties in order to fasten and improve bone consolidation and healing and combined with active molecules, therefore acting as local drug delivery device. In this joint collaboration agreement, each party will file its own patents, allowing TheraVet to strengthen its intellectual property position with new proprietary bone substitutes.